GRAIL, Inc. Restructuring Charges
GRAIL, Inc. (GRAL) reported Restructuring Charges of $19.01 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2024-11-13
- GRAIL, Inc. restructuring charges for the quarter ending 2024-09-30 was $19.01M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 9 month |
|---|---|---|
| 2024-09-30 | $19.01M 10-Q · filed 2024-11-13 | $19.01M 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |